The global regenerative medicine market size was estimated to be USD 30.44 billion in 2023 and is expected to reach at USD 168.00 billion by 2034 with a CAGR of 16.80% during the forecast period 2024-2034. Rising advancements in biological therapies, a gradual preference towards personalized medicinal approaches over conventional treatments, increasing incidence of degenerative disorders, a heightened focus on researching novel regenerative therapies & the development of gene-based treatments, a robust product pipeline is undergoing clinical trials, supported by government & private funding, growing technological progress in tissue engineering & nanotechnology, growing adoption of adaptive regulatory approaches, rising number of stem cell therapies in clinical trials for chronic diseases, heightened emphasis on research & development activities, and surge in regulatory approvals for regenerative medicines are the several pivotal factors driving the expansion of the market.
Surge in regulatory approvals for regenerative medicines is predicted to boost the market growth during the forecast period. Regenerative medicines possess a distinctive capacity to modify the fundamental mechanisms of diseases. Ongoing trials of regenerative therapies offer hopeful remedies for particular chronic conditions with unaddressed medical requirements. For instance, in October 2023, Editas Medicine, Inc. has reported that the FDA awarded Regenerative Medicine Advanced Therapy (RMAT) status to EDIT-301, a gene editing drug currently in the research phase. This designation is specifically for addressing severe sickle cell disease (SCD).
By product, therapeutics was the highest revenue-grossing segment in the global regenerative medicine market in 2023 owing to the aging population is expanding, leading to elevated occurrences of age-related & degenerative disorders, a heightened emphasis on developing alternative treatment options, and increase in regulatory approvals. For instance, in April 2022, Kite, a subsidiary of Gilead, has disclosed the receipt of approval from the U.S. FDA for its CAR T-cell therapy product, Yescarta. This authorization allows for the utilization of Yescarta in the treatment of large B-cell lymphoma that is refractory or has relapsed. Additionally, banks is predicted to grow at the fastest CAGR during the forecast period owing to the growing trend in the utilization of cell-based & tissue engineering methods in medical applications, increase in the availability of services from banks catering to non-research purposes, surge in the number of clinical trials exploring stem cell & tissue-based regenerative therapies.
By application, oncology was the highest revenue-grossing segment in the global regenerative medicine market in 2023 owing to the increasing incidence of cancer, a higher need for effective treatment solutions in the field, increase in investments in cancer research, specifically directed towards the advancement of regenerative & advanced cell therapies, and collaborations among market participants are on the rise. For instance, in January 2023, Calidi Biotherapeutics (CBT) and First Light Acquisition Group (FLAG) have established a collaborative agreement with the objective of transforming oncolytic virotherapies using stem cell-based platforms. Additionally, cardiovascular is predicted to grow at the fastest CAGR during the forecast period owing to the advancements in cell-based therapies & regenerative medicines are on the upswing, an increasing adoption of both single & mixed cells sourced from autologous & allogeneic origins to investigate their impact on cardiovascular diseases (CVDs), numerous significant players are actively engaged in the creation of regenerative therapies aimed at repairing, restoring, & revascularizing damaged tissues in the heart.
By end-user, hospital was the highest revenue-grossing segment in the global regenerative medicine market in 2023 owing to the rise in the number of surgeries, increasing government backing through policy harmonization. This support serves as a catalyst for major companies providing these products, leading to a surge in approvals by regulatory bodies. For instance, in February 2023, The gene therapy developed by CSL Behring and UniQure has been granted approval by the European Commission for Hemgenix, marking a significant milestone in the treatment of hemophilia B. Additionally, clinics is predicted to grow at the fastest CAGR during the forecast period owing to the growing trend of clinics undergoing privatization to offer specialized regenerative medicine services, particularly focusing on the treatment of musculoskeletal conditions. These services aim to alleviate pain and enhance the healing process.
North America region is anticipated for the highest revenue share during the forecast period owing to the presence of both government and private funding for developmental initiatives, advanced technological frameworks facilitating the swift detection of chronic diseases, substantial healthcare expenditure, and numerous ongoing clinical trial processes in the field of regenerative medicine. For instance, in June 2022, CRISPR Therapeutics shared encouraging outcomes from the ongoing phase 1 COBALT-LYM trial, which assessed the safety and effectiveness of CTX130. This allogeneic CAR-T cell therapy, wholly owned by CRISPR Therapeutics, is designed to target CD70 for the treatment of both solid tumors and specific hematologic malignancies. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the swift integration of cell-based approaches in healthcare, an aging population on the rise, rapid expansion of infrastructure and facilities to expedite stem cell research, and an increasing number of mergers and acquisitions among market participants. For instance, in April 2022, Metcela Inc. has completed the acquisition of Japan Regenerative Medicine Co., Ltd., which was previously a wholly-owned subsidiary of Kidswell Bio Co., Ltd. With this acquisition, Metcela has expanded its product portfolio by incorporating JRM-001, an autologous cell product designed for pediatric congenital heart disease. This move is aimed at enhancing Metcela's clinical development infrastructure for such products.
Surge in regulatory approvals for regenerative medicines is predicted to boost the market growth during the forecast period. Regenerative medicines possess a distinctive capacity to modify the fundamental mechanisms of diseases. Ongoing trials of regenerative therapies offer hopeful remedies for particular chronic conditions with unaddressed medical requirements. For instance, in October 2023, Editas Medicine, Inc. has reported that the FDA awarded Regenerative Medicine Advanced Therapy (RMAT) status to EDIT-301, a gene editing drug currently in the research phase. This designation is specifically for addressing severe sickle cell disease (SCD).
By product, therapeutics was the highest revenue-grossing segment in the global regenerative medicine market in 2023 owing to the aging population is expanding, leading to elevated occurrences of age-related & degenerative disorders, a heightened emphasis on developing alternative treatment options, and increase in regulatory approvals. For instance, in April 2022, Kite, a subsidiary of Gilead, has disclosed the receipt of approval from the U.S. FDA for its CAR T-cell therapy product, Yescarta. This authorization allows for the utilization of Yescarta in the treatment of large B-cell lymphoma that is refractory or has relapsed. Additionally, banks is predicted to grow at the fastest CAGR during the forecast period owing to the growing trend in the utilization of cell-based & tissue engineering methods in medical applications, increase in the availability of services from banks catering to non-research purposes, surge in the number of clinical trials exploring stem cell & tissue-based regenerative therapies.
By application, oncology was the highest revenue-grossing segment in the global regenerative medicine market in 2023 owing to the increasing incidence of cancer, a higher need for effective treatment solutions in the field, increase in investments in cancer research, specifically directed towards the advancement of regenerative & advanced cell therapies, and collaborations among market participants are on the rise. For instance, in January 2023, Calidi Biotherapeutics (CBT) and First Light Acquisition Group (FLAG) have established a collaborative agreement with the objective of transforming oncolytic virotherapies using stem cell-based platforms. Additionally, cardiovascular is predicted to grow at the fastest CAGR during the forecast period owing to the advancements in cell-based therapies & regenerative medicines are on the upswing, an increasing adoption of both single & mixed cells sourced from autologous & allogeneic origins to investigate their impact on cardiovascular diseases (CVDs), numerous significant players are actively engaged in the creation of regenerative therapies aimed at repairing, restoring, & revascularizing damaged tissues in the heart.
By end-user, hospital was the highest revenue-grossing segment in the global regenerative medicine market in 2023 owing to the rise in the number of surgeries, increasing government backing through policy harmonization. This support serves as a catalyst for major companies providing these products, leading to a surge in approvals by regulatory bodies. For instance, in February 2023, The gene therapy developed by CSL Behring and UniQure has been granted approval by the European Commission for Hemgenix, marking a significant milestone in the treatment of hemophilia B. Additionally, clinics is predicted to grow at the fastest CAGR during the forecast period owing to the growing trend of clinics undergoing privatization to offer specialized regenerative medicine services, particularly focusing on the treatment of musculoskeletal conditions. These services aim to alleviate pain and enhance the healing process.
North America region is anticipated for the highest revenue share during the forecast period owing to the presence of both government and private funding for developmental initiatives, advanced technological frameworks facilitating the swift detection of chronic diseases, substantial healthcare expenditure, and numerous ongoing clinical trial processes in the field of regenerative medicine. For instance, in June 2022, CRISPR Therapeutics shared encouraging outcomes from the ongoing phase 1 COBALT-LYM trial, which assessed the safety and effectiveness of CTX130. This allogeneic CAR-T cell therapy, wholly owned by CRISPR Therapeutics, is designed to target CD70 for the treatment of both solid tumors and specific hematologic malignancies. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the swift integration of cell-based approaches in healthcare, an aging population on the rise, rapid expansion of infrastructure and facilities to expedite stem cell research, and an increasing number of mergers and acquisitions among market participants. For instance, in April 2022, Metcela Inc. has completed the acquisition of Japan Regenerative Medicine Co., Ltd., which was previously a wholly-owned subsidiary of Kidswell Bio Co., Ltd. With this acquisition, Metcela has expanded its product portfolio by incorporating JRM-001, an autologous cell product designed for pediatric congenital heart disease. This move is aimed at enhancing Metcela's clinical development infrastructure for such products.
Segmentation: Regenerative Medicine Market Report 2023 - 2034
Regenerative Medicine Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Therapeutics
- Gene Therapies
- Cell-based Immunotherapies
- Stem Cell & Progenitor Cell-based therapeutics
- Allogenic
- Autologous
- Others
- Primary Cell-based Therapeutics
- Musculoskeletal
- Dermatology
- Dental
- Surgical
- Others
- Tools
- Banks
- Services
Regenerative Medicine Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Immunology & Inflammation
- Musculoskeletal
- Ophthalmology
- Cardiovascular
- Dermatology
- Oncology
- Others
Regenerative Medicine Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Clinics
- Hospitals
- Others
Regenerative Medicine Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Regenerative Medicine Market: Product Estimates & Trend Analysis
8. Regenerative Medicine Market: Application Estimates & Trend Analysis
9. Regenerative Medicine Market: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Regenerative Medicine Market
12. Europe Global Regenerative Medicine Market
13. Asia Pacific Global Regenerative Medicine Market
14. Latin America Global Regenerative Medicine Market
15. MEA Global Regenerative Medicine Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Integra Lifesciences Corp.
- Pfizer Inc.
- AstraZeneca plc
- Bayer AG
- Vericel Corp.
- Novartis AG
- Merck KGaA
- Astellas Pharma Inc.
- Abbott
- F. Hoffmann-La Roche Ltd.
- Cook Biotech Inc.
- GlaxoSmithKline (GSK)
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 30.44 Billion |
| Forecasted Market Value ( USD | $ 168 Billion |
| Compound Annual Growth Rate | 16.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
